{"id":"NCT03681184","sponsor":"Alnylam Pharmaceuticals","briefTitle":"A Study to Evaluate Lumasiran in Children and Adults With Primary Hyperoxaluria Type 1","officialTitle":"ILLUMINATE-A: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study With an Extended Dosing Period to Evaluate the Efficacy and Safety of Lumasiran in Children and Adults With Primary Hyperoxaluria Type 1","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-11-27","primaryCompletion":"2019-11-05","completion":"2024-01-12","firstPosted":"2018-09-21","resultsPosted":"2021-01-19","lastUpdate":"2024-08-12"},"enrollment":39,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Primary Hyperoxaluria Type 1 (PH1)"],"interventions":[{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Lumasiran","otherNames":["ALN-GO1"]}],"arms":[{"label":"Placebo/Lumasiran","type":"PLACEBO_COMPARATOR"},{"label":"Lumasiran/Lumasiran","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to evaluate the efficacy and safety of lumasiran in children and adults with primary hyperoxaluria type 1 (PH1).","primaryOutcome":{"measure":"Percent Change in 24-hour Urinary Oxalate Excretion Corrected for Body Surface Area (BSA) From Baseline to Month 6","timeFrame":"Baseline to Month 6","effectByArm":[{"arm":"Placebo/Lumasiran","deltaMin":-11.8,"sd":3.8},{"arm":"Lumasiran/Lumasiran","deltaMin":-65.4,"sd":2.9}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"6 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":10},"locations":{"siteCount":17,"countries":["United States","France","Germany","Israel","Netherlands","Switzerland","United Arab Emirates","United Kingdom"]},"refs":{"pmids":["33789010"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":13},"commonTop":["Injection site reaction","Headache","Abdominal pain","COVID-19","Rhinitis"]}}